CY1126699T1 - Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας - Google Patents

Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας

Info

Publication number
CY1126699T1
CY1126699T1 CY20241100181T CY241100181T CY1126699T1 CY 1126699 T1 CY1126699 T1 CY 1126699T1 CY 20241100181 T CY20241100181 T CY 20241100181T CY 241100181 T CY241100181 T CY 241100181T CY 1126699 T1 CY1126699 T1 CY 1126699T1
Authority
CY
Cyprus
Prior art keywords
anemia
compositions
methods
therapeutic treatment
therapeutic
Prior art date
Application number
CY20241100181T
Other languages
Greek (el)
English (en)
Inventor
Robert Shalwitz
Charlotte HARTMAN
Akshay BUCH
Isaiah SHALWITZ
John JANUSZ
Joseph Gardner
Original Assignee
Akebia Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52022903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126699(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics, Inc. filed Critical Akebia Therapeutics, Inc.
Publication of CY1126699T1 publication Critical patent/CY1126699T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20241100181T 2013-06-13 2024-03-08 Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας CY1126699T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361834808P 2013-06-13 2013-06-13
US201361889478P 2013-10-10 2013-10-10
US201361898890P 2013-11-01 2013-11-01
US201361898885P 2013-11-01 2013-11-01
US201361912185P 2013-12-05 2013-12-05

Publications (1)

Publication Number Publication Date
CY1126699T1 true CY1126699T1 (el) 2025-05-09

Family

ID=52022903

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20241100181T CY1126699T1 (el) 2013-06-13 2024-03-08 Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας
CY2024016C CY2024016I2 (el) 2013-06-13 2024-06-04 Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2024016C CY2024016I2 (el) 2013-06-13 2024-06-04 Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας

Country Status (37)

Country Link
US (2) US11857543B2 (enExample)
EP (2) EP3007695B1 (enExample)
JP (6) JP2016521747A (enExample)
KR (4) KR102461176B1 (enExample)
CN (3) CN114404413A (enExample)
AU (4) AU2014278543B2 (enExample)
BR (1) BR112015031027A2 (enExample)
CA (2) CA3151685A1 (enExample)
CL (2) CL2015003602A1 (enExample)
CY (2) CY1126699T1 (enExample)
DK (1) DK3007695T3 (enExample)
DO (1) DOP2015000297A (enExample)
EC (1) ECSP20058592A (enExample)
ES (1) ES2974273T3 (enExample)
FI (2) FI3007695T3 (enExample)
FR (1) FR24C1025I2 (enExample)
HR (1) HRP20240319T1 (enExample)
HU (2) HUE066123T2 (enExample)
IL (3) IL243047B (enExample)
LT (2) LT3007695T (enExample)
MX (3) MX378150B (enExample)
MY (1) MY204336A (enExample)
NL (1) NL301278I2 (enExample)
NO (1) NO2024025I1 (enExample)
NZ (3) NZ753904A (enExample)
PE (2) PE20201496A1 (enExample)
PH (2) PH12015502738B1 (enExample)
PL (1) PL3007695T3 (enExample)
PT (1) PT3007695T (enExample)
RS (1) RS65341B1 (enExample)
RU (2) RU2019134558A (enExample)
SG (2) SG11201509998WA (enExample)
SI (1) SI3007695T1 (enExample)
SM (1) SMT202400092T1 (enExample)
TW (5) TWI856464B (enExample)
WO (1) WO2014200773A2 (enExample)
ZA (1) ZA201509024B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485264T1 (de) 2006-06-26 2010-11-15 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2014170832A1 (en) 2013-04-16 2014-10-23 Koninklijke Philips N.V. System and method for biventricular pacemaker pulse detection in surface ecg
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX374909B (es) * 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
CN108401429A (zh) * 2016-12-06 2018-08-14 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
IL278533B1 (en) 2018-05-09 2025-10-01 Akebia Therapeutics Inc Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
PH12022551040A1 (en) * 2019-10-31 2023-05-29 Akebia Therapeutics Inc Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
JP2023518392A (ja) * 2020-03-17 2023-05-01 ザイダス ライフサイエンシズ リミティド Ｈｉｆプロリルヒドロキシラーゼ阻害剤を含む製剤組成物
AU2021263829A1 (en) * 2020-04-29 2022-12-15 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
JP2023530452A (ja) 2020-06-19 2023-07-18 アケビア セラピューティクス インコーポレイテッド バダデュスタットの薬物間相互作用の調節
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
KR20230130035A (ko) * 2021-01-08 2023-09-11 아케비아 테라퓨틱스 인코포레이티드 바다두스타트를 사용하는 치료 방법
IL305487A (en) 2021-03-01 2023-10-01 Akebia Therapeutics Inc Modulation of drug-drug interactions by VADADUSTAT

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (enExample) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1 (de) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2000509047A (ja) 1996-04-30 2000-07-18 ヘキスト・アクチエンゲゼルシヤフト ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1080075B1 (en) 1998-03-23 2004-08-11 Aventis Pharmaceuticals Inc. Piperididinyl and n-amidinopiperidinyl derivatives
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
WO1999063970A1 (en) 1998-06-11 1999-12-16 Pharmacia & Upjohn Company Delavirdine tablet formulation
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003053997A2 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2004019868A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JP2008500834A (ja) 2004-05-28 2008-01-17 ファイブローゲン、インコーポレーテッド Ｈｉｆプロリルヒドロキシラーゼ活性アッセイ
TW200609218A (en) 2004-05-31 2006-03-16 Tanabe Seiyaku Co Bicyclic compounds
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
MX2008008608A (es) 2006-01-09 2009-03-04 Btg Int Ltd Moduladores de factor i inducible por hipoxia y usos relacionados.
EP1983823A1 (en) 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
ATE485264T1 (de) 2006-06-26 2010-11-15 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
GB2444904B (en) 2006-12-05 2008-11-05 Michael Hilary Burke A Process For The Preparation of an Orally Administrable Unit Dose Tablet
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
WO2008125388A1 (en) 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
AU2008241503A1 (en) 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
WO2008141731A2 (en) 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN101868251B (zh) 2007-08-06 2012-10-10 千寿制药株式会社 含有HIF-1α和HIF-2α表达抑制物质的药物
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011505367A (ja) 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
ES2383273T3 (es) 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
CA2736732A1 (en) 2008-09-15 2010-03-18 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US8137666B2 (en) * 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
EP3708163A1 (en) 2009-03-31 2020-09-16 Ligand Pharmaceuticals, Inc. Use of sparsentan for the treatment of chronic inflammatory diseases
KR101772963B1 (ko) 2009-03-31 2017-08-31 깃세이 야쿠힌 고교 가부시키가이샤 인돌리진 유도체 및 그 의약용도
HRP20140705T1 (hr) 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
CN105979779A (zh) 2013-08-16 2016-09-28 俄亥俄州国家创新基金会 调整dna甲基化的组合物和方法
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
JP2017503835A (ja) 2014-01-23 2017-02-02 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 眼球疾患治療のための組成物及び方法
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
AU2016235534A1 (en) 2015-03-20 2017-10-12 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
KR20210100594A (ko) 2018-10-03 2021-08-17 아케비아 테라퓨틱스 인코포레이티드 염증성 장애의 치료에 사용하기 위한 벤조이미다졸 유도체
US11524939B2 (en) * 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
EP4360706A2 (en) 2024-05-01
PE20160194A1 (es) 2016-04-20
FR24C1025I2 (fr) 2025-06-20
RU2019134558A (ru) 2020-02-20
HRP20240319T1 (hr) 2024-05-24
IL243047B (en) 2019-11-28
KR20240055172A (ko) 2024-04-26
CN114404413A (zh) 2022-04-29
SG11201509998WA (en) 2016-01-28
NO2024025I1 (no) 2024-05-29
JP6612479B2 (ja) 2019-11-27
AU2024205219A1 (en) 2024-09-19
EP3007695B1 (en) 2024-02-07
IL270335B (en) 2021-03-25
CN114404414A (zh) 2022-04-29
CA3151685A1 (en) 2014-12-18
KR20210043760A (ko) 2021-04-21
CY2024016I1 (el) 2025-05-09
US11857543B2 (en) 2024-01-02
KR20220151008A (ko) 2022-11-11
IL281058B1 (en) 2023-04-01
CA2914662A1 (en) 2014-12-18
BR112015031027A2 (pt) 2017-08-29
PT3007695T (pt) 2024-03-07
TW201534302A (zh) 2015-09-16
RS65341B1 (sr) 2024-04-30
AU2020200903A1 (en) 2020-02-27
JP2020033369A (ja) 2020-03-05
AU2014278543B2 (en) 2019-11-14
LT3007695T (lt) 2024-03-25
MY204336A (en) 2024-08-23
JP2021191773A (ja) 2021-12-16
EP4360706A3 (en) 2024-07-10
KR102660040B1 (ko) 2024-04-24
LTPA2024521I1 (enExample) 2024-07-10
MX2015017229A (es) 2016-04-19
JP2023145717A (ja) 2023-10-11
MX2022003510A (es) 2022-05-16
FI3007695T3 (fi) 2024-03-13
MX391198B (es) 2025-03-21
US20160143891A1 (en) 2016-05-26
EP3007695A4 (en) 2017-05-31
AU2020200903B2 (en) 2021-11-04
MX2020006963A (es) 2022-03-30
TWI650126B (zh) 2019-02-11
TW202339743A (zh) 2023-10-16
AU2022200570B2 (en) 2024-05-02
NZ714963A (en) 2020-07-31
EP3007695A2 (en) 2016-04-20
SMT202400092T1 (it) 2024-05-14
SG10201910773VA (en) 2020-01-30
TW201922244A (zh) 2019-06-16
CN105451739A (zh) 2016-03-30
CL2018002372A1 (es) 2018-12-28
ZA201509024B (en) 2019-05-29
TW202446394A (zh) 2024-12-01
JP7672455B2 (ja) 2025-05-07
NZ753905A (en) 2020-07-31
AU2022200570A1 (en) 2022-02-17
CY2024016I2 (el) 2025-05-09
HK1216844A1 (en) 2016-12-09
HUS2400023I1 (hu) 2024-07-28
TWI791177B (zh) 2023-02-01
AU2014278543A1 (en) 2016-01-07
FR24C1025I1 (fr) 2024-07-26
TWI856464B (zh) 2024-09-21
ECSP20058592A (es) 2020-10-30
RU2016100363A (ru) 2017-07-18
KR20160023773A (ko) 2016-03-03
JP2016521747A (ja) 2016-07-25
IL281058B2 (en) 2023-08-01
RU2016100363A3 (enExample) 2018-05-15
RU2705206C2 (ru) 2019-11-06
PL3007695T3 (pl) 2024-07-01
WO2014200773A3 (en) 2015-03-05
ES2974273T3 (es) 2024-06-26
JP2019163293A (ja) 2019-09-26
JP2025114609A (ja) 2025-08-05
DK3007695T3 (da) 2024-03-18
JP7328291B2 (ja) 2023-08-16
SI3007695T1 (sl) 2024-04-30
TW202133843A (zh) 2021-09-16
KR102373245B1 (ko) 2022-03-17
NL301278I2 (nl) 2024-08-01
PH12015502738A1 (en) 2016-03-07
CL2015003602A1 (es) 2016-07-29
PE20201496A1 (es) 2020-12-29
NZ753904A (en) 2020-07-31
CA2914662C (en) 2022-05-31
JP6937812B2 (ja) 2021-09-22
IL281058A (en) 2021-04-29
PH12020551705A1 (en) 2021-11-15
MX378150B (es) 2025-03-10
TWI712411B (zh) 2020-12-11
WO2014200773A2 (en) 2014-12-18
KR102461176B1 (ko) 2022-11-01
HUE066123T2 (hu) 2024-07-28
US20240335434A1 (en) 2024-10-10
FIC20240023I1 (fi) 2024-06-25
PH12015502738B1 (en) 2021-12-10
DOP2015000297A (es) 2016-03-15

Similar Documents

Publication Publication Date Title
CY2024016I1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας
IL280443A (en) Exon skipping compositions for treating muscular dystrophy
CY2023025I2 (el) Αντι-pdi αντισωματα και η χρηση τους ως θεραπευτικοι και διαγνωστικοι παραγοντες
IL282202A (en) Compositions and methods for personalized neoplasia vaccines
FR21C1059I1 (fr) Compositions pharmaceutiques
IL263175B (en) Microbiota restoration therapy (mrt), compositions and methods of manufacture
EP3164406C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
HUE039997T2 (hu) Szulfamoilpirrolamid származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerekként
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
HUE047699T2 (hu) Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
PT3277270T (pt) Composições e métodos de tratamento de anemia
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
LT3007726T (lt) Tautopatijos gydymo būdai
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
HUE046723T2 (hu) Töltõanyag-készítmény lipoatrófia kezelésére
DK2777689T3 (da) Ny farmaceutisk sammensætning til behandling af svampeinfektioner
FI20135231A7 (fi) Potilasalusta
EP2967102A4 (en) COMPOSITIONS AND METHODS OF ACTIVATING BDNF
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények